These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 3322727)

  • 1. U-100 insulin gives some protection against metabolic deterioration due to CSII interruption.
    Scheen AJ; Henrivaux P; Jandrain B; Lefèbvre PJ
    Diabetes Care; 1987; 10(6):707-11. PubMed ID: 3322727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolic alterations after a two-hour nocturnal interruption of a continuous subcutaneous insulin infusion.
    Scheen A; Castillo M; Jandrain B; Krzentowski G; Henrivaux P; Luyckx AS; Lefèbvre PJ
    Diabetes Care; 1984; 7(4):338-42. PubMed ID: 6381007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sandostatin, a new analogue of somatostatin, reduces the metabolic changes induced by the nocturnal interruption of continuous subcutaneous insulin infusion in type 1 (insulin-dependent) diabetic patients.
    Scheen AJ; Gillet J; Rosenthaler J; Guiot J; Henrivaux P; Jandrain B; Lefèbvre PJ
    Diabetologia; 1989 Nov; 32(11):801-9. PubMed ID: 2687064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of metabolic deterioration between insulin analog and regular insulin after a 5-hour interruption of a continuous subcutaneous insulin infusion in type 1 diabetic patients.
    Guerci B; Meyer L; Sallé A; Charrié A; Dousset B; Ziegler O; Drouin P
    J Clin Endocrinol Metab; 1999 Aug; 84(8):2673-8. PubMed ID: 10443658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The degree/rapidity of the metabolic deterioration following interruption of a continuous subcutaneous insulin infusion is influenced by the prevailing blood glucose Level.
    Castillo MJ; Scheen AJ; Lefèbvre PJ
    J Clin Endocrinol Metab; 1996 May; 81(5):1975-8. PubMed ID: 8626867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention of metabolic alterations by insulin supplements administered either before or after 2-h nocturnal interruption of CSII.
    Scheen AJ; Henrivaux P; Jandrain B; Paolisso G; Lefèbvre PJ
    Diabetes Care; 1987; 10(5):567-72. PubMed ID: 3315513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 1. Metabolic and hormonal consequences and scheme for a prompt return to adequate control.
    Krzentowski G; Scheen A; Castillo M; Luyckx AS; Lefèbvre PJ
    Diabetologia; 1983 May; 24(5):314-8. PubMed ID: 6347779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of insulin antibodies on metabolic deterioration after interruption of continuous subcutaneous insulin infusion.
    Montaña E; Fernández-Castañer M; Rosel P; Gómez JM; Vinzia C; Soler J
    Diabete Metab; 1990; 16(3):220-5. PubMed ID: 2210017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overnight metabolic control with bedtime injection of intermediate-acting insulin or continuous subcutaneous insulin infusion.
    Olsson PO; Arnqvist H; Von Schenck H; Ottosson AM
    Diabetes Care; 1987; 10(6):702-6. PubMed ID: 3322726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Lack of benefit from the intermittent administration of insulin in treatment using subcutaneous perfusion pump in type 1 diabetes].
    Lilet H; Krzentowski G; Bodson A; Scheen AJ; Lefebvre PJ
    Diabete Metab; 1991; 17(3):363-72. PubMed ID: 1884881
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.
    Attia N; Jones TW; Holcombe J; Tamborlane WV
    Diabetes Care; 1998 May; 21(5):817-21. PubMed ID: 9589247
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved postprandial metabolic control after subcutaneous injection of a short-acting insulin analog in IDDM of short duration with residual pancreatic beta-cell function.
    Pampanelli S; Torlone E; Ialli C; Del Sindaco P; Ciofetta M; Lepore M; Bartocci L; Brunetti P; Bolli GB
    Diabetes Care; 1995 Nov; 18(11):1452-9. PubMed ID: 8722069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous subcutaneous insulin infusion treatment in insulin-dependent diabetic patients: a comparison with conventional optimized treatment in a long-term study.
    Calabrese G; Bueti A; Santeusanio F; Giombolini A; Zega G; Angeletti G; Cartechini MG; Brunetti P
    Diabetes Care; 1982; 5(5):457-65. PubMed ID: 7188333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-insulin antibodies and metabolic deterioration after interruption of continuous subcutaneous insulin infusion.
    Scheen AJ; Henrivaux P; Jandrain B; Lefebvre PJ
    Diabetes Care; 1986; 9(6):673-4. PubMed ID: 3803158
    [No Abstract]   [Full Text] [Related]  

  • 15. Overnight interruption of wearing insulin pump: substitution dose and injection site of insulin.
    Helve E; Pelkonen R; Koivisto VA
    Diabetes Care; 1986; 9(6):565-9. PubMed ID: 3542449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Free insulin levels and metabolic effects of meal-time bolus and square-wave intraperitoneal insulin infusion in insulin-dependent diabetic patients.
    Jimenez JT; Walford S; Home PD; Hanning I; Alberti KG
    Diabetologia; 1985 Oct; 28(10):728-33. PubMed ID: 3905470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Metabolic consequences of a 6-hour interruption of a continuous subcutaneous insulin infusion pump in insulin-dependent diabetic patients].
    Scheen AJ
    Rev Med Liege; 1987 Nov; 42(21):837-52. PubMed ID: 2892242
    [No Abstract]   [Full Text] [Related]  

  • 18. A 6-hour nocturnal interruption of a continuous subcutaneous insulin infusion: 2. Marked attenuation of the metabolic deterioration by somatostatin.
    Scheen AJ; Krzentowski G; Castillo M; Lefèbvre PJ; Luyckx AS
    Diabetologia; 1983 May; 24(5):319-25. PubMed ID: 6135635
    [No Abstract]   [Full Text] [Related]  

  • 19. Near normalization of metabolism of IDDM: comparison of continuous subcutaneous (CSII) versus intraperitoneal (CIPII) insulin delivery.
    Gooch BR; Abumrad NN; Robinson RP; Crofford OB
    Horm Metab Res; 1984 Dec; 16 Suppl 1():190-4. PubMed ID: 6398261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of continuous subcutaneous insulin infusion: metabolic deterioration and glycaemic autoregulation after deliberate cessation of infusion.
    Pickup JC; Viberti GC; Bilous RW; Keen H; Alberti KG; Home PD; Binder C
    Diabetologia; 1982 Mar; 22(3):175-9. PubMed ID: 7042428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.